Ziemssen, Focke
Agostini, Hansjürgen
Feltgen, Nicolas
Finger, Robert P.
Haritoglou, Christos
Hoerauf, Hans
Iwersen, Matthias
Porstner, Martina
Clemens, Andreas
Gmeiner, Benjamin
Article History
Received: 9 September 2021
Accepted: 28 January 2022
First Online: 18 February 2022
Competing interests
: F. Z.: Consultant: Alimera Sciences, Allergan/Abbvie, Bayer, Boehringer-Ingelheim, Novartis, NovoNordisk, MSD, Oxurion, Roche/Genentech; Speaker: Alimera, Allergan/Abbvie, Bayer, BDI, CME Health, Novartis, ODOS, Roche, Research: Bayer, BMBF, Clearside, DFG, Kodiak, Iveric, Ophtea, Novartis, Regeneron, R. H. A.: No competing interests. N. F.: Consultant: Alimera Sciences, Novartis, and Roche; Speaker: Allergan, Alimera, Bayer, Heidelberg Engineering, Novartis, and Roche. R. P. F.: Personal Fees: Novartis, Bayer, Roche/Genentech, Böhringer-Ingelheim, Allergan, Alimera, Chiesi, ProQR, Ellex, Santhera, Opthea. Research Support: Novartis, Heidelberg Engineering, Zeiss Meditec, CentreVue, Biogen. C. H.: Consultant: Allergan; Speaker: Bayer, Novartis. H. H.: Consultant: Allergan, Bayer, Novartis; Speaker: Allergan, Bayer, Novartis; Shareholder: Bayer, Novartis. M. I. reports full time employment at Novartis Pharma GmbH. M. P. reports full time employment at Novartis Pharma GmbH. A. C. reports full time employment and shareholder of Novartis Pharma AG. B. G. reports full time employment at Novartis Pharma GmbH and shareholder of Novartis Pharma AG.